GD2/CD56 Bi-specific CAR-T Cell Therapy
NCT05437328
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
60
Enrollment
OTHER
Sponsor class
Conditions
Malignant Disease
Interventions
BIOLOGICAL:
bi-4SCAR GD2/CD56 T cells
Sponsor
Shenzhen Geno-Immune Medical Institute